Beam Therapeutics Q2 2024 Earnings Report $30.43 -2.71 (-8.18%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Beam Therapeutics EPS ResultsActual EPS-$1.11Consensus EPS -$1.13Beat/MissBeat by +$0.02One Year Ago EPS-$1.08Beam Therapeutics Revenue ResultsActual Revenue$11.80 millionExpected Revenue$14.18 millionBeat/MissMissed by -$2.38 millionYoY Revenue Growth-41.30%Beam Therapeutics Announcement DetailsQuarterQ2 2024Date8/6/2024TimeBefore Market OpensConference Call ResourcesPress ReleaseBEAM Earnings HistoryPowered by Beam Therapeutics Earnings HeadlinesCathie Wood’s ARK Investment buys 171K shares of Beam Therapeutics todayFebruary 21 at 5:58 AM | markets.businessinsider.comNew proton beam therapy precisely targets and destroys cancer cellsFebruary 20 at 12:20 PM | msn.comWarning: Elon’s $20k Robot Might Replace Your NannyTesla’s Robot Revolution Has Begun It’s official… Tesla’s robot revolution is underway… By the end of this year, Tesla plans to produce 600 new “Tesla Bots” per week… Tech insiders believe this could be the company’s next core driver of explosive growth. Some even believe it could be the catalyst that would push shares above the $1,000 mark. That’s essentially a 100% increase from today’s price…February 22, 2025 | WealthPress (Ad)Brokerages Set Beam Therapeutics Inc. (NASDAQ:BEAM) Target Price at $47.67February 16, 2025 | americanbankingnews.comBMO Capital maintains Outperform on Beam Therapeutics stockFebruary 11, 2025 | msn.comH.C. Wainwright maintains $80 target on Beam Therapeutics stockFebruary 4, 2025 | msn.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM), a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
